查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1596760

胃癌治疗市场：治疗方法、适应症、药物类别、给药途径、分销管道分类 - 全球预测 2025-2030

Stomach Cancer Treatment Market by Treatment, Disease Indication, Drug Class, Route of Administration, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年胃癌治疗市场价值为50.9亿美元，预计到2024年将达到55.5亿美元，复合年增长率为9.53%，到2030年将达到96.3亿美元。

胃癌治疗的范围和定义包括旨在控制和治癒胃癌的各种治疗方法，包括手术、化疗、标靶治疗和免疫治疗。胃癌是全球癌症相关死亡的首要原因之一，证明了治疗的必要性，因此需要有效的治疗策略来改善患者的预后和存活率。胃癌治疗对于个人化医疗的应用至关重要，个人化医疗根据个体的遗传倾向和癌症的分子特征量身定制治疗方法，从而促进更精确和有效的治疗方法。最终用途范围主要包括医院、癌症研究中心和专门的癌症诊所，多学科团队正在这些地方部署这些治疗方法来治疗胃癌。

主要市场统计
基准年[2023] 50.9亿美元
预测年份 [2024] 55.5亿美元
预测年份 [2030] 96.3亿美元
复合年增长率（%） 9.53%

有几个关键的成长要素推动了市场格局，特别是标标靶治疗的进步和盛行率的增加，推动了对创新治疗方案的需求。健康意识的提高和诊断技术的改进也有助于市场成长，因为它们有利于早期发现和及时干预。此外，下一代免疫疗法和联合治疗方案的开发也出现了新的潜在机会，并有望提高疗效和患者的生活品质。鼓励公司投资合作研究和临床试验来释放这些机会。

然而，市场开拓面临限制和挑战，例如治疗成本高、患者对治疗的反应不同以及发展中地区获得先进治疗方案的机会有限。监管障碍和进行全球认可的临床试验的复杂性使市场扩张更加复杂。为了发展我们的业务，我们将透过专注于早期检测和治疗反应监测的生物标记、增强药物输送系统以及利用人工智慧来优化治疗途径来推动创新。市场竞争激烈且研究密集型，需要持续创新和策略联盟才能保持竞争力并有效解决未满足的需求。

市场动态：快速发展的胃癌治疗市场的关键市场洞察

供给和需求的动态交互作用正在改变胃癌治疗市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 胃癌高风险的老年人口增加
    • 久坐和不健康的生活方式导致糖尿病和肥胖症增加
    • 越来越重视早期筛检和早期发现
  • 市场限制因素
    • 胃肠病专家短缺，及时诊断所需的检测和治疗方法有限
  • 市场机会
    • 胃癌治疗和诊断方法的持续技术进步
  • 市场挑战
    • 治疗相关的副作用

波特五力：驾驭胃癌治疗市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解外部对胃癌治疗市场的影响

外部宏观环境因素在塑造胃癌治疗市场的表现动态中起着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解胃癌治疗市场的竞争状况

对胃癌治疗市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示自己的竞争定位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV定位矩阵胃癌治疗市场供应商绩效评估

FPNV定位矩阵是评估胃癌治疗市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议绘製胃癌治疗市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对胃癌治疗市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 胃癌高风险的老年人口增加
      • 由于缺乏运动和不健康的生活习惯，糖尿病和肥胖患者不断增加。
      • 早期筛检和检测的重要性日益增加
    • 抑制因素
      • 胃肠病专家短缺，及时诊断所需的扫描和治疗手段有限
    • 机会
      • 胃癌治疗方法和诊断技术不断进步
    • 任务
      • 治疗相关的副作用
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章依治疗分類的胃癌治疗市场

  • 化疗
  • 免疫疗法
  • 放射治疗及手术
  • 标靶治疗

第七章胃癌治疗市场：依疾病适应症分类

  • 胃癌/胃食道结合部癌
  • 胃肠道基质肿瘤

第八章按药物类别分類的胃癌治疗市场

  • HER2拮抗剂
  • PD-1/PD-L1抑制剂
  • VEGFR2拮抗剂

第九章胃癌治疗市场：依途径

  • 可注射的
  • 口服

第10章胃癌治疗市场：依通路划分

  • 医院药房
  • 专业药局和零售药局

第十一章 美洲胃癌治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章亚太地区胃癌治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十三章欧洲、中东和非洲胃癌治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • AstraZeneca PLC
  • Bayer AG
  • Bristol Myers Squibb Company
  • Celltrion Healthcare Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann La Roche Ltd.
  • GlaxoSmithKline PLC
  • Imugene Limited
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Merck KGaA
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer, Inc.
  • Samsung Bioepis Co., Ltd.
Product Code: MRR-F927BA461E32

The Stomach Cancer Treatment Market was valued at USD 5.09 billion in 2023, expected to reach USD 5.55 billion in 2024, and is projected to grow at a CAGR of 9.53%, to USD 9.63 billion by 2030.

The scope and definition of stomach cancer treatment encompass various therapeutic approaches aimed at managing or curing gastric cancer, including surgery, chemotherapy, targeted therapy, and immunotherapy. The necessity for treatment is underscored by the global burden of stomach cancer, as it ranks among the leading causes of cancer-related deaths worldwide, necessitating effective treatment strategies to improve patient outcomes and survival rates. Stomach cancer treatment is crucial in the application of personalized medicine, where therapies are tailored to the individual's genetic makeup and the cancer's molecular profile, fostering more precise and effective treatment regimens. The end-use scope primarily includes hospitals, cancer research centers, and specialized oncology clinics, where multidisciplinary teams deploy these treatments in the management of gastric cancer.

KEY MARKET STATISTICS
Base Year [2023] USD 5.09 billion
Estimated Year [2024] USD 5.55 billion
Forecast Year [2030] USD 9.63 billion
CAGR (%) 9.53%

Market insights reveal several key growth factors influencing the stomach cancer treatment landscape, notably advancements in targeted therapies and the increasing prevalence of the disease, which drives demand for innovative treatment options. Rising health awareness and improved diagnostic technologies also contribute to market growth, as they facilitate early detection and timely intervention. Moreover, the latest potential opportunities lie in developing next-generation immunotherapies and combination treatment regimens that promise to enhance efficacy and patient quality of life. Companies are recommended to invest in research collaborations and clinical trials to unlock these opportunities.

However, the market faces limitations and challenges including high treatment costs, variability in patient response to therapies, and limited access to advanced treatment options in developing regions. Regulatory hurdles and the complexity of conducting globally accepted clinical trials further complicate market expansion. For business growth, innovation can be driven by focusing on biomarkers for early detection and monitoring treatment response, enhancing drug delivery systems, and leveraging artificial intelligence to optimize treatment pathways. The nature of the market is highly competitive and research-intensive, necessitating continuous innovation and strategic partnerships to maintain a competitive edge and address unmet clinical needs effectively.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Stomach Cancer Treatment Market

The Stomach Cancer Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising geriatric population with a high risk for the development of stomach cancer
    • Increasing cases of diabetic and obese patients coupled with sedentary & unhealthy lifestyle
    • Growing emphasis on early screening and detection
  • Market Restraints
    • Dearth of gastroenterologists professionals and limited availability of scanning & treatment for timely diagnosis
  • Market Opportunities
    • Continuous technological advancements in treatments and diagnostic methods for stomach cancer
  • Market Challenges
    • Side effects related to treatments

Porter's Five Forces: A Strategic Tool for Navigating the Stomach Cancer Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Stomach Cancer Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Stomach Cancer Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Stomach Cancer Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Stomach Cancer Treatment Market

A detailed market share analysis in the Stomach Cancer Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Stomach Cancer Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Stomach Cancer Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Stomach Cancer Treatment Market

A strategic analysis of the Stomach Cancer Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Stomach Cancer Treatment Market, highlighting leading vendors and their innovative profiles. These include AstraZeneca PLC, Bayer AG, Bristol Myers Squibb Company, Celltrion Healthcare Co., Ltd., Eli Lilly and Company, F. Hoffmann La Roche Ltd., GlaxoSmithKline PLC, Imugene Limited, Jiangsu Hengrui Medicine Co., Ltd., Merck KGaA, Novartis AG, Otsuka Pharmaceutical Co., Ltd., Pfizer, Inc., and Samsung Bioepis Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Stomach Cancer Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment, market is studied across Chemotherapy, Immunotherapy, Radiation Therapy & Surgery, and Targeted Therapy.
  • Based on Disease Indication, market is studied across Gastric Cancer/Gastroesophageal Junction Cancer and Gastrointestinal Stromal Tumors.
  • Based on Drug Class, market is studied across HER2 Antagonists, PD-1/PD-L1 Inhibitors, and VEGFR2 Antagonists.
  • Based on Route of Administration, market is studied across Injectable and Oral.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies and Specialty & Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising geriatric population with a high risk for the development of stomach cancer
      • 5.1.1.2. Increasing cases of diabetic and obese patients coupled with sedentary & unhealthy lifestyle
      • 5.1.1.3. Growing emphasis on early screening and detection
    • 5.1.2. Restraints
      • 5.1.2.1. Dearth of gastroenterologists professionals and limited availability of scanning & treatment for timely diagnosis
    • 5.1.3. Opportunities
      • 5.1.3.1. Continuous technological advancements in treatments and diagnostic methods for stomach cancer
    • 5.1.4. Challenges
      • 5.1.4.1. Side effects related to treatments
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Stomach Cancer Treatment Market, by Treatment

  • 6.1. Introduction
  • 6.2. Chemotherapy
  • 6.3. Immunotherapy
  • 6.4. Radiation Therapy & Surgery
  • 6.5. Targeted Therapy

7. Stomach Cancer Treatment Market, by Disease Indication

  • 7.1. Introduction
  • 7.2. Gastric Cancer/Gastroesophageal Junction Cancer
  • 7.3. Gastrointestinal Stromal Tumors

8. Stomach Cancer Treatment Market, by Drug Class

  • 8.1. Introduction
  • 8.2. HER2 Antagonists
  • 8.3. PD-1/PD-L1 Inhibitors
  • 8.4. VEGFR2 Antagonists

9. Stomach Cancer Treatment Market, by Route of Administration

  • 9.1. Introduction
  • 9.2. Injectable
  • 9.3. Oral

10. Stomach Cancer Treatment Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Hospital Pharmacies
  • 10.3. Specialty & Retail Pharmacies

11. Americas Stomach Cancer Treatment Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Stomach Cancer Treatment Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Stomach Cancer Treatment Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AstraZeneca PLC
  • 2. Bayer AG
  • 3. Bristol Myers Squibb Company
  • 4. Celltrion Healthcare Co., Ltd.
  • 5. Eli Lilly and Company
  • 6. F. Hoffmann La Roche Ltd.
  • 7. GlaxoSmithKline PLC
  • 8. Imugene Limited
  • 9. Jiangsu Hengrui Medicine Co., Ltd.
  • 10. Merck KGaA
  • 11. Novartis AG
  • 12. Otsuka Pharmaceutical Co., Ltd.
  • 13. Pfizer, Inc.
  • 14. Samsung Bioepis Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. STOMACH CANCER TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. STOMACH CANCER TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES STOMACH CANCER TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES STOMACH CANCER TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. STOMACH CANCER TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. STOMACH CANCER TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. STOMACH CANCER TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. STOMACH CANCER TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY RADIATION THERAPY & SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY GASTRIC CANCER/GASTROESOPHAGEAL JUNCTION CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY HER2 ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY PD-1/PD-L1 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY VEGFR2 ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY SPECIALTY & RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES STOMACH CANCER TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 63. AUSTRALIA STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 64. AUSTRALIA STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 68. CHINA STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 69. CHINA STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. INDIA STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 74. INDIA STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. INDONESIA STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 79. INDONESIA STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 83. JAPAN STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 84. JAPAN STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 88. MALAYSIA STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 89. MALAYSIA STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 90. MALAYSIA STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 93. PHILIPPINES STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 94. PHILIPPINES STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 95. PHILIPPINES STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 98. SINGAPORE STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 99. SINGAPORE STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 100. SINGAPORE STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 103. SOUTH KOREA STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 104. SOUTH KOREA STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 108. TAIWAN STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 109. TAIWAN STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 110. TAIWAN STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 113. THAILAND STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 114. THAILAND STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 115. THAILAND STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 118. VIETNAM STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 119. VIETNAM STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 120. VIETNAM STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 129. DENMARK STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 130. DENMARK STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 131. DENMARK STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 134. EGYPT STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 135. EGYPT STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 136. EGYPT STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 139. FINLAND STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 140. FINLAND STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 141. FINLAND STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 144. FRANCE STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 145. FRANCE STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 146. FRANCE STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 149. GERMANY STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 150. GERMANY STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 151. GERMANY STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 154. ISRAEL STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 155. ISRAEL STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 156. ISRAEL STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 159. ITALY STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 160. ITALY STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 161. ITALY STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 164. NETHERLANDS STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 165. NETHERLANDS STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 166. NETHERLANDS STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 169. NIGERIA STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 170. NIGERIA STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 171. NIGERIA STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 174. NORWAY STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 175. NORWAY STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 176. NORWAY STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 179. POLAND STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 180. POLAND STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 181. POLAND STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 184. QATAR STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 185. QATAR STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 186. QATAR STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 189. RUSSIA STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 190. RUSSIA STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 191. RUSSIA STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 194. SAUDI ARABIA STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 195. SAUDI ARABIA STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 196. SAUDI ARABIA STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 199. SOUTH AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 200. SOUTH AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 204. SPAIN STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 205. SPAIN STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 206. SPAIN STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 209. SWEDEN STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 210. SWEDEN STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 211. SWEDEN STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 214. SWITZERLAND STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 215. SWITZERLAND STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 216. SWITZERLAND STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 219. TURKEY STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 220. TURKEY STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 221. TURKEY STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 224. UNITED ARAB EMIRATES STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 225. UNITED ARAB EMIRATES STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED KINGDOM STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED KINGDOM STOMACH CANCER TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM STOMACH CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 234. STOMACH CANCER TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 235. STOMACH CANCER TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023